Summary of Medicenna Therapeutics FY Conference Call Company Overview - Medicenna Therapeutics is a publicly listed clinical-stage immunotherapy company focused on developing "evolutionary superkines" to address unmet needs in oncology [2][24] - The company is listed on the Toronto Stock Exchange and OTCQX [2] Key Programs 1. **MDNA11** - A best-in-class IL-2 superkine, the only long-acting IL-2 super agonist not enhanced by alpha-beta [2] - Demonstrated response rates of 30% to 50% in checkpoint failed patients [3] - Phase 1/2 trials are ongoing, with data expected from over 425 patients by year-end [6][24] - Safety profile shows over 90% of adverse events were grade one or two, with no dose-limiting toxicities observed [12][13] 2. **MDNA113** - A first-in-class targeted anti-PD-1 bispecific, currently in preclinical proof of concept [3] - Combines an anti-PD-1 with the IL-2 superkine from MDNA11, aiming to enhance efficacy [19][20] 3. **Bizaxofusp (MDNA55)** - An IL-4 empowered superkine targeting end-stage recurrent glioblastoma, showing doubled survival rates compared to standard care (from 7 months to nearly 14 months) [3][23] - The company is seeking to partner this asset [4][24] Clinical Data and Expectations - By the end of the year, clinical data from 250 patients with aggressive tumors is expected [4][24] - Completion of the phase 1/2 ability trial and data disclosure on MDNA11 in monotherapy and combination with Keytruda® [4][24] - Non-human primate testing of the bifunctional superkine is also anticipated [24] Market Opportunity - The market for MDNA11 is significant, particularly for patients with recurrent melanoma and MSI-high tumors, who currently have limited treatment options [17] - The combination of MDNA11 with checkpoint inhibitors could potentially improve response rates from 30%-40% to 60%-70% [18] Financial Overview - Medicenna has a cash position of $21 million, projected to last until Q3 of the following year [24] - The company has approximately 83 million shares outstanding, with insiders owning about 22% [24] Conclusion - Medicenna Therapeutics is positioned to make significant advancements in immunotherapy with its innovative superkine platform, particularly in oncology, with multiple programs showing promising clinical data and a strong market opportunity ahead [2][24]